[et_pb_section fb_built=”1″ use_custom_gutter=”on” specialty=”on” parallax_method_1=”off” parallax_method_2=”off” module_class=”m-special-section-modifier et_pb_specialty_fullwidth” _builder_version=”3.22″ inner_width=”89%” inner_width_tablet=”80%” inner_width_phone=”” inner_width_last_edited=”on|desktop” inner_max_width=”89%” inner_max_width_tablet=”80%” inner_max_width_phone=”” inner_max_width_last_edited=”on|desktop” custom_padding=”|||” transparent_background=”off” make_fullwidth=”on”][et_pb_column type=”3_4″ specialty_columns=”3″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_row_inner admin_label=”Row” _builder_version=”3.25″ custom_padding=”23.7188px|0px|0|0px|false|false”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”Post content” _builder_version=”4.4.5″ text_line_height=”1.6em” background_size=”initial” background_position=”top_left” background_repeat=”repeat” module_alignment=”left” hover_enabled=”0″ text_font_size_tablet=”15px” text_font_size_phone=”14px” text_font_size_last_edited=”on|phone” use_border_color=”off”]

Major depressive disorder (MDD) is the third leading cause of global disability [1], yet not everyone diagnosed with the condition seek treatment. Roughly 43% of primary care patients who experience a 6-month anxiety or depressive disorder diagnosis do not receive treatment, with most preferring self-management [2]. Contributing factors deterring patients to seek treatment include side effects associated with antidepressant medications and the need for frequent psychotherapy sessions with specialized professionals. Device-based interventions, such as electroconvulsive therapy, repetitive transcranial magnetic stimulation, and vagus nerve stimulation are approved as third- or fourth-line treatments for medication-resistant depression. 

Transcranial photobiomodulation (t-PBM), which is comprised of delivering near-infrared (NIR) light through the skull to the brain, has emerged as a potential antidepressant treatment in both animal models and human studies.

This paper reports the results from the Elated-2 Pilot Trial, a single-site, randomized, double-blind, sham-controlled study on the effect of t-PBM in MDD patients. The study is comprised of 21 adult MDD patients age 18 to 65, who underwent twice weekly t-BPM sessions for 8 weeks. The study finds subjects receiving t-PBM with NIR light showed greater improvement than the sham group that did not receive any light therapy. Furthermore, t-PBM with NIR light demonstrated antidepressant properties with a medium to large effect size in patients with MDD. 

References
[1] Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital, Boston, Massachusetts.
[2] LiteCure LLC, Newark, Delaware.

[/et_pb_text][/et_pb_column_inner][/et_pb_row_inner][et_pb_row_inner _builder_version=”3.25″][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_cta button_url=”https://niraxxlife.wpengine.com/wp-content/uploads/2020/03/2018-Cassano-PLS-ELATED.pdf” url_new_window=”on” button_text=”Read publication” _builder_version=”4.4.5″ header_text_color=”#000000″ background_color=”#feb215″ background_layout=”light” hover_enabled=”0″ body_font_size_tablet=”” body_font_size_phone=”14px” body_font_size_last_edited=”on|phone” body_font_size=”14px”]

Cassano, P. et al. (2018). Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot Trial. Photomedicine and Laser Surgery,  XX, XX.

[/et_pb_cta][/et_pb_column_inner][/et_pb_row_inner][/et_pb_column][et_pb_column type=”1_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_sidebar area=”custom-sidebar-1″ _builder_version=”3.17.6″][/et_pb_sidebar][/et_pb_column][/et_pb_section]